Literature DB >> 1908750

The stability of mesna in beverages and syrup for oral administration.

M P Goren1, B A Lyman, J T Li.   

Abstract

We evaluated the stability of the aqueous formulation of mesna during storage in syringes and after dilution in beverages and syrups. Measurements of the concentrations of mesna showed that the undiluted formulation was stable for at least 9 days in standard polypropylene syringes at 5 degrees, 24 degrees, and 35 degrees C. There was no detectable oxidation of mesna to dimesna over the course of at least 1 week when mesna was diluted 1:2 and 1:5 in syrups and incubated at 24 degrees C in capped tubes. Concentration changes were clinically negligible for 1:2, 1:10, and 1:100 dilutions of mesna in six carbonated drinks, two juices, and milk after incubation for 24 h at 5 degrees C. Thus, the aqueous mesna formulation is stable when diluted and stored in a variety of beverages and syrups under conditions suitable for oral administration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1908750     DOI: 10.1007/bf00685538

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

Review 1.  Mesna--a short review.

Authors:  I C Shaw; M I Graham
Journal:  Cancer Treat Rev       Date:  1987-06       Impact factor: 12.111

2.  Infusion of ifosfamide plus mesna.

Authors:  C G Rowland; E Bradford; P Adams; R P Haines-Nutt; K Jakobson
Journal:  Lancet       Date:  1984-08-25       Impact factor: 79.321

3.  Sensitive quantitative analysis of disulfide bonds in polypeptides and proteins.

Authors:  T W Thannhauser; Y Konishi; H A Scheraga
Journal:  Anal Biochem       Date:  1984-04       Impact factor: 3.365

4.  Reassessment of Ellman's reagent.

Authors:  P W Riddles; R L Blakeley; B Zerner
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing.

Authors:  I C Shaw; M S Weeks
Journal:  Eur J Cancer Clin Oncol       Date:  1987-07

6.  Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.

Authors:  C A James; T G Mant; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

7.  Mesna excretion and ifosfamide nephrotoxicity in children.

Authors:  M P Goren; C B Pratt; W H Meyer; R K Wright; R K Dodge; M J Viar
Journal:  Cancer Res       Date:  1989-12-15       Impact factor: 12.701

8.  Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing.

Authors:  M S Jones; R D Murrell; I C Shaw
Journal:  Eur J Cancer Clin Oncol       Date:  1985-05

9.  Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.

Authors:  C E Araujo; J Tessler
Journal:  Eur J Cancer Clin Oncol       Date:  1983-02

10.  Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.

Authors:  K Ormstad; S Orrenius; T Låstbom; N Uehara; J Pohl; J Stekar; N Brock
Journal:  Cancer Res       Date:  1983-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.